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Abstract
Background: Porcine epidemic diarrhea virus (PEDV) is a highly contagious virus infecting pigs of all ages with
high morbidity and mortality among newborn piglets. Currently, there is no effective vaccine available to protect
the pigs from PEDV. The N-terminal subunit of spike protein (S1) is responsible for virus binding to the cellular
receptor and contains a number of neutralizing antibody epitopes. Thus, we expressed and produced recombinant
S1 protein to protect newborn piglets by immunization of sows.
Methods: Affinity tagged PEDV S1 protein was expressed in a secretory form in yeast, insect and mammalian cells
to identify the most suitable production system. Purified recombinant protein was analysed by SDS-PAGE, Western
blot and deglycosylation assay. A pregnant sow was intramuscularly immunized three times with adjuvanted
recombinant protein prior to farrowing. PEDV-specific immune responses in sera and colostrum of the sow and
piglets were assayed by ELISA and virus neutralization assays. Piglets were challenged orally with PEDV, and clinical
parameters were monitored for 6 days post-challenge.
Results and conclusion: Of three eukaryotic expression systems tested (yeast, insect-cell, and mammalian),
expression by HEK-293 T cells gave the highest yield of protein that was N-glycosylated and was the most
appropriate candidate for vaccination. Administration of the subunit vaccine in a sow resulted in induction of
S1-specific IgG and IgA that were passively transferred to the suckling piglets. Also, high virus neutralization titres
were observed in the serum of the vaccinated sow and its piglets. After PEDV challenge, piglets born to the
vaccinated sow exhibited less severe signs of disease and significantly lower mortality compared to the piglets of a
control sow. However, there were no significant differences in diarrhea, body weight and virus shedding. Thus,
vaccination with S1 subunit vaccine failed to provide complete protection to suckling piglets after challenge
exposure, and further improvements are needed for the development of a subunit vaccine that fully protects
against PEDV infection.
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Background
Porcine epidemic diarrhea virus (PEDV) is an enveloped,
positive-stranded RNA virus which readily infects pigs,
resulting in highly contagious porcine epidemic diarrhea
[1]. PEDV belongs to family Coronaviridae, subfamily
Coronavirinae and genus Alphacoronavirus [2]. Some
viruses of the Coronaviridae family cause severe disease
in humans such as severe acute respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory
syndrome coronavirus (MERS-CoV) [3, 4]. Corona-
viruses of veterinary significance include avian infec-
tious bronchitis virus infecting chickens, transmissible
gastroenteritis virus (TGEV) infecting pigs, bovine cor-
onavirus, feline coronaviruses, canine coronavirus and
turkey coronavirus [5].* Correspondence: alex.zak@usask.ca
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Porcine epidemic diarrhea (PED) was first observed in
Europe in the early 1970s, and PEDV was first isolated
in Belgium in 1978 [6]. Subsequently, PED has become
an endemic disease in Asian pig farming countries.
Severe PED outbreaks were reported in China in
2010–2012 [7, 8]. From April 2013 to the present,
major PEDV outbreaks have been reported in the
USA [9], Canada [10], Taiwan [11] and Europian
countries [12, 13]. The PED is characterized by the
presence of watery diarrhea in the infected piglets in
first few weeks of their life, dehydration, vomiting
and anorexia resulting in high morbidity and mortal-
ity [14]. PEDV infection of older pigs results in
considerably lower morbidity and mortality. The
symptoms of the disease are similar to transmissible
gastroenteritis of pigs and hence only laboratory tests
can aid in differencial diagnosis [15]. Although, some
efforts have been made to create the vaccine against
PEDV with varied success, no effective vaccine is available
in the market to protect the newborn piglets [14, 15].
The size of PEDV genomic RNA is about 28 kb, and
contains seven open reading frames (ORFs) encoding
viral proteins: 1A, 1B, spike (S), ORF3, envelope (E),
membrane (M) and nucleocapsid (N). The S protein is
present at the outer surface of the virion and is 1386
amino acid long [16]. The spike protein of coronaviruses
forms trimers and plays an important role in the virus
attachment and in virus-cell membrane fusion [17].
Porcine aminopeptidase N has been demonstrated to be
a functional receptor for the PEDV coronavirus [18].
The S protein of PEDV is a class I membrane glycopro-
tein consisting of two subunits: the N-terminal S1 and
the C-terminal S2. Cleavage of spike protein into S1 and
S2 is an essential event in the cellular entry for wild-type
PEDV virus but not for cell culture adapted PEDV [19].
Proteolytic cleavage of spike protein in PEDV needs
trypsin [19, 20]. Several neutralizing epitopes have been
identified on the S protein sequence [21–23], and the
recombinant S1 protein was previously shown to have
protective activity in piglets [24].
Results and discussion
Expression of S1 in yeast cells
Initial attempts to express the S1 protein in the bacterial
cells were not successful (data not shown), which may be
due to problems in processing of the S1 protein in prokary-
otic cells. Therefore, we used PichiaPink (Pichia pastoris)
yeast cells to express S1 from a synthetic S1 gene codon
optimized for yeast and containing a C-terminal histidine-
tag to aid purification. Initially, the time course was per-
formed for the expression of the S1 protein in the yeast
cells over the period of 4 days. Western blot analysis of the
cell culture medium of transformed yeast cells resulted in
the detection of a specific 35–40 kDa band when probed
with anti-his antibody (Fig. 1a). The observed protein mo-
lecular weight was less than the expected 80.9 kDa mo-
lecular weight of un-glycosylated S1. This may be due to
the cleavage of the protein by yeast protease. The purified
protein was detected in SDS-PAGE as a smearing band in
a range of 40–70 kDa (Fig. 1b). The band pattern may be
the result of glycosylation of multiple sites in the S1 protein
by the yeast cells. The yield of the purified protein from
one liter of yeast culture was found to be 180 μg.
Expression of S1 by recombinant baculovirus
To increase the PEDV S1 protein yield and to achieve a
full-length S1 protein expression, a baculovirus expres-
sion system was employed. To this end, histidine-tagged
PEDV S1 gene was cloned into a BACMID containing
the genome of baculovirus, transfected into Sf9 cells and
the recombinant baculovirus was recovered. Small scale
PEDV S1 protein expression in the recombinant baculo-
virus infected cells was analysed by Western blotting
using the anti-his antibody at days 1 to 7 post-infection
(Fig. 2a). The S1 protein was detected as a distinct
100 kDa band and band intensity increased on each sub-
sequent day. Size and integrity of affinity purified S1
from the cell culture medium of baculovirus infected
cells was found to be of the same size (Fig. 2b) as de-
tected earlier (Fig. 2a) with the yield of 3.9 mg/L.
Expression of S1 in mammalian cells
Mammalian expression of S1 utilizing a human CMV
promoter within an episomal vector was also investi-
gated. In preliminary experiments, expression of S1 in
which the native signal peptide was replaced with that of
tissue plaminogen activator (TPA) was compared with
expression of S1 containing native signal peptide. Trans-
formed HEK-293 T cells were grown for 24 h in serum
free medium, and the supernatant was then analysed by
Western blotting for expression of histidine-tagged pro-
tein. The S1 protein was detected as a single 130 kDa
band for both cells expressing S1 with native signal pep-
tide and cells expressing S1 with TPA (Fig. 3a). However,
the presence of TPA substantially enhanced expression
of S1. Therefore, S1 with TPA was subsequently used for
production and purification of the vaccine antigen. Af-
finity purified S1 protein was analysed on SDS-PAGE by
Coomassie blue staining and found to be of the expected
size (Fig. 3b). The yield of the S1 protein from HEK
293 T cell culture medium was found to be 30 mg/L,
which was 10 and 100-fold higher than the yields ob-
tained from insect cells or yeast cells respectively.
Glycosylation profile of the purified S1 protein
As there are multiple glycosylation sites present in the
spike proteins of other coronaviruses, the purified PEDV
S1 protein was analysed for glycosylation. Sensitivity to
Makadiya et al. Virology Journal  (2016) 13:57 Page 2 of 10
glycosidases PNGase F (removes N-linked glycans) and
O-glycosidase (removes O-linked glycans) was used to
determine the nature of glycosylation of the recombin-
ant protein.
PNGase F, but not O-glycosidase, increased the
electrophoretic mobility of purified recombinant S1
produced by both HEK-293 T or baculovirus-infected
cells (Fig. 4) suggesting that the recombinant protein
is N- but not O-glycosylated when produced by either
mammalian or insect cells.
Humoral immune responses in sows
To determine the immunogenicity of the S1-based
subunit vaccine, a pregnant sow was immunized
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Fig. 2 Expression of the recombinant PEDV S1 protein in insect Sf9 cells. a A small scale S1 protein expression experiment was
performed by infecting Sf9 cells with recombinant baculovirus expressing PEDV S1 gene. Cell culture media were collected on
indicated days post-infection and analysed by Western blotting using anti-his antibody. b Large scale S1 protein purification was
performed on cell culture medium of the cells infected with recombinant baculovirus at day 7 post-infection, and the purified protein
was anyalzed by SDS-PAGE and stained by Coomassie Blue. Medium from un-infected cells served as a negative control. Numbers on
the left indicate the protein molecular marker size in kDa
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Fig. 1 Expression of the recombinant PEDV S1 protein in PichiaPink Pichia pastoris. a A small scale S1 protein expression experiment was
performed, and samples of culture medium were collected on indicated days post-induction and detected by Western blotting using anti-his
antibody. b A large scale S1 protein purification was performed from the yeast cell supernatant at day 4 post-induction, and the purified protein
was anyalzed by staining of SDS-PAGE by silver nitrate. Medium from the un-induced cells served as a negative control. Numbers on the left
indicate the protein molecular marker size in kDa
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intramuscularly with adjuvanted S1 recombinat pro-
tein produced from HEK 293 T cells. The humoral
immune responses elicited by the subunit vaccine
were examined by ELISA and serum neutralization
assay. The vaccinated sow showed an increase in S1-
specific serum IgG titer after the first, second and
third vaccination (Fig. 5a) whereas no increase was
noticed in the control sow. Furthermore, in contrast
to the control sow, vaccinated sow demonstrated de-
tectable serum neutralizing-antibody titers at day 11
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Fig. 4 Deglycosylation analysis of the purified recombinant S1 proteins. S1 proteins purified from cell culture media of HEK 293 T cells or baculovirus
infected Sf9 cells were treated with deglycosylation enzymes PNGase F or O-Glycosidase or left un-treated. Proteins were resolved on 10 % SDS-PAGE
and analysed by Western blotting using anti-his antibody. Numbers on the left indicate the protein molecular marker size in kDa
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Fig. 3 Expression of the recombinant PEDV S1 protein in HEK 293 T cells. a Cells were grown to confluency in 6 well plates. The DMEM was
replaced with serum free medium (either SFM4HEK293; lane 1 or Opti-MEM; lane 2) and incubated further for 24 h before analyzing culture
supernatant by Western blotting with anti-his antibody. The S1 was expressed with native signal peptide (S SP) or with TPA signal peptide (TPA
SP). A negative control was HEK-293 T cells that had not been transfected. b Analysis of the purified S1 protein by Coomassie Blue staining of
SDS-PAGE. Numbers on the left indicate the protein molecular marker size in kDa
Makadiya et al. Virology Journal  (2016) 13:57 Page 4 of 10
post-vaccination, and by 28 days the titers had in-
creased 100-fold (Fig. 5b). In contrast to ELISA titers
(Fig. 5a), virus neutralizing titers did not increase
after the third immunization of sow by day 35
(Fig. 5b).
Piglets that regularly suckle the immune mother receive
colostrum/milk antibody, a process that cofers passive im-
munity to the piglets. Therefore, we tested colostrum sam-
ples collected from the vaccinated and control sows on
the day of farrowing for the presense of PEDV S1-specific
IgA and IgG antibody titres. The IgA and IgG titers were
higher in colostrum of the vaccinated sow compared to
the control sow (Fig. 5c and d). The IgG titer levels were
5-fold higher than IgA titer levels, but it is not surprising
since IgG is the major isotype in sow colostrum whereas
IgA predominates in milk [25].
Humoral immune responses in piglets
Sera of piglets, collected on day 4 after birth, had high
titres of S1-specific IgG in the litter of a vaccinated sow,
while no titres were found in the litter of a control sow
(Fig. 6a). These data indicate that passive transfer of
S1-specific IgG antibodies occurred between the vac-
cinated pregnant sow and the offspring via colos-
trum/milk. In addition, these specific antibodies also
conferred virus neutralization (Fig. 6b).
a
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Fig. 5 PEDV S1-specific antibody responses in sows. a Sow serum IgG titers were measured at the indicated time points post-vaccination
by ELISA using the recombinant purified S1 protein as an antigen. Sows were vaccinated three times on days 0, 14 and 28 as indicated
by arrows. b Virus-neutralizing antibody titers in sera from sows collected at indicated time points post-vaccination. c Colostrum IgA titers
and d colostrum IgG titers were determinded by ELISA. Colostrum samples were collected on the day of farrowing
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Virus shedding in challenged piglets
Virus shedding in feces of piglets collected at different
time points post challenge was assessed by a PEDV N
gene-based real-time RT-PCR, and the cycle threshold
(CT) values are shown in Fig. 7. No differences were ob-
served in PEDV shedding between groups of piglets of
vaccinated and control sow.
Clinical observations
There were no adverse reactions noticed at the injection
site or overall health of sow post-vaccination. Each day
post-challenge, the piglets were evaluated by animal ser-
vices veterinarian for the clinical scores. The clinical
score was assigned as 0 (healthy) to 4 (dead or mori-
bund) for each piglet based on parameters such as ani-
mal demeanor, degree of depression and willingness to
nurse. The average clinical scores for the vaccinated
sow’s piglets was close to zero, whereas the control sow’s
piglets had average scores reaching on day 2 and 3 post-
challenge (Fig. 8a). Similarly, fecal scores were recorded
from 0 (normal pasty faces) to 2 (watery diarrhea) for all
the piglets each day post-challenge. Diarrhea increased
until day 4 post-challenge and then started to reduce for
both groups of piglets (Fig. 8b).
The weight of each piglet was monitored every day
post-farrowing for 10 days, and the analysis of the aver-
age weight of piglets showed no appreciable differences
between two groups of piglets (Fig. 8c).
Survival of the piglets was monitored for 10 days after
challenge. At 6 days post-challenge, 7 out of 8 piglets
(87.5 %) of vaccinated sow survived whereas only 3 out
of 7 piglets (42.9 %) of control sow survived the chal-
lenge (Fig. 8d). Statistically significant (P = 0.0002) better
survival rate in the litter of vaccinated sow can be ex-
plained by the fact that these piglets were less depressed
and showed more willingness to nurse than piglets of a
control sow. However, more experiments with large
number of sows are needed to confirm these data.
In summary, our vaccine had negligible effect in ei-
ther preventing diarrhea or preventing PEDV-mediated
weight loss, but did partially protect piglets in terms of
severity of clinical disease and significantly reduced mor-
tality. Future work to improve the protective efficacy of
the subunit vaccine for PEDV may include testing new
adjuvants. For instance, in the recently published report,
oil-in-water adjuvant was used to formulate recombin-
ant S1 protein [24]. Another approach is use of oral
immunization instead of intramuscular (IM) route. A
field study demonstrated that orally vaccinated sows
with live attenuated PEDV vaccine exhibited higher
IgA and virus neutralizing antibody levels in the col-
ostrum or sera compared to those of the counterparts
Fig. 7 Virus shedding in piglets. PEDV viral RNA was extracted from
rectal swabs of challenged piglets and assessed by real-time reverse
transcription PCR
ba
*
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Fig. 6 PEDV S1-specific antibody titers in piglets. a Piglet serum IgG titers were measured on the day of PEDV challenge by ELISA. The values
represent the mean IgG titers of litters from a vaccinated sow (n = 8) and litters (n = 7) of an unvaccinated control sow. Error bars represent the
standard deviation. b Virus-neutralizing antibody titers in sera from piglets at the day of PEDV challenge. The error bars represent the standard
deviation of the mean. * means significantly different results (P < 0.001)
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administered the IM vaccine with the same dose [26].
To deliver a recombinant protein orally, a live vector
such as adenoviral vector might be used [27].
Conclusions
Amongst three eukaryotic expression systems, the high-
est production of S1 was achieved using a mammalian
expression with the TPA signal sequence. This method
of expression can be used to produce large amount of S1
for vaccine, diagnostic and research purposes.
A sow vaccinated three times with the S1 subunit vac-
cine had high IgG titres and high virus neutralization ti-
tres in the serum as compared to the control sow. Also,
high levels of IgG and IgA titers were found in the col-
ostrum of the vaccinated sow. Furthermore, maternal
transfer of antibody was demonstrated as only the serum
of suckling piglets had high titres of S1 specific IgG and
viral-neutralizing antibody. There was higher survival
rate among of piglets of vaccinated sow (87.5 %) than in
the piglets of control sow (42.9 %) after oral PEDV
challenge (P = 0.0002). These survival rates suggest the
potential of the S1 protein subunit vaccine in pre-
venting piglet mortality. The vaccinated sow’s piglets
exhibited lower clinical signs of disease except diar-
rhea throughout the six day post-challenge period
than control piglets. Surprisingly, there was no differ-
ence in average weight and PEDV shedding among
two groups of piglets. These observations suggest the
inability of the S1 subunit vaccine in our experiment
to control all PED clinical signs although more exper-
iments involving a large number of sows are needed
to confirm these findings.
Methods
Cells and virus
Human embryo kidney (HEK) 293 T (ATCC CRL-1573)
and Vero 76 (ATCC CRL-1587) cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 50 μg/mL gentamycin and 10 % fetal bo-
vine serum. PichiaPink Strain 1 (Invitrogen) was grown
in YPD medium. Insect Sf9 cells (Gibco) were grown in
Sf-900 serum-free medium (ThermoFisher Scientific).
ca
db
Fig. 8 Protective efficacy of the vaccine. Litters from a vaccinated (n = 8) and a control sow (n = 7) were orally challenged with virulent PEDV at
4 days of age. Clinical (a), fecal scores (b), average weight (c) and survival of piglets (d) were evaluated
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PEDV strain USA/Colorado/2013 (GeneBank acces-
sion no. KF272920) was provided by Diagnostic Virology
Laboratory (NVLS, Ames, USA), and the virus was
propagated on Vero 76 cells in DMEM containing
50 μg/mL gentamycin, 2 μg/mL TPCK-trypsin and 0.2 %
bovine serum albumin.
Expression of recombinant S1 protein in yeast cells
Yeast codon optimized PEDV S1 gene (coding animo
acids 1–734) with the 3’-end polyhistidine coding se-
quence was synthesized by GenScript. Synthetic S1 gene
was digested with restriction enzymes MlyI-KpnI and
cloned into the pPinkα-HC vector (ThermoFisher Scien-
tific) into StuI-KpnI sites. Expression of the recombinant
protein was performed as recommended by manufac-
turers (ThermoFisher Scientific). Briefly, PichiaPink
strain 1 (ade2−) was electroporated with pPinkα-S1 line-
arized plasmid DNA and plated on PAD (Pichia Adenine
Dropout) agar plates for selecting transformants. After
incubation at 30 °C for 5 days, white colonies were
screened for expression of S1. Recombinant yeast cells
were grown in buffered glycerol-complex medium
(BMGY) and induction was performed in buffered
methanol-complex medium (BMMY) with 0.5 %
methanol. To prevent non-specific cleavage of S1 pro-
tein by yeast cell proteases, aprotinin and phenyl-
methylsulfonyl fluoride (PMSF) were added during the
induction phase at 1 μg/mL each. Yeast cells were
grown at 30 °C for 4 days and centrifuged at 3000 g for
5 min at room temperature and supernatant was col-
lected for protein purification.
Expression of recombinant S1 protein in insect cells
S1 coding region of PEDV genome was PCR amplified
using primers (5’-TCCGATGAATTCGCCACCATGAA
GTCACTCACCTATTTTTGG-3’ and 5’- CTAGATCTC
GAGTCAGTGGTGATGATGGTGGTGGAAGCCAGG
GAGTTCGCGG-3’). The resulting PCR product was
cloned into the XhoI, EcoRI sites of pFastBac vector
(ThermoFisher Scientific). Cellfectin® II Reagent (Ther-
moFisher Scientific) was used for transfecting Sf9 cells
in Grace’s insect cell culture medium (ThermoFisher
Scientific) for generating recombinant baculovirus. All
the steps of generating the recombinant baculovirus full
length genome, screening, rescue of recombinant
baculovirus and large scale production of S1 protein in
Sf9 cells was performed according to manufacturer’s
recommendations for Bac-to-Bac Baculovirus Expres-
sion System (ThermoFisher Scientific). Briefly, the Sf9
cells were grown at 30 °C for 24 h in the Sf-900 II SFM
(ThermoFisher Scientific) at an orbital shaker incubator
in two 1 L flasks (500 mL culture volume). Sf9 cells
were infected with the recombinant baculovirus at an
MOI of 1 and kept for 7 days in the incubator for
secretion of the recombinant S1 protein. The super-
natant was collected by centrifuging the insect cells at
500 g for 5 min at room temperature.
Expression of recombinant S1 protein in mammalian cells
The S1 ORF plus C-terminal his10 tag (codon optimized
for mammalian expression) together with a proceeding
Kozak sequence, was cloned downstream of a human
CMV promoter plus intron, contained within an in-
house episomal vector; elements downstream of the S1
ORF included a woodchuck hepatitis post-transcriptional
regulatory element and bovine growth hormone poly-
adenylation site (DNA sequence of constructs are avail-
able upon request). Constructs were transfected into
HEK293T cells using Turbofect (ThermoFisher Scientific)
according to the manufacturer’s instructions. Cells stably
maintaining the episomal constructs were selected by
puromycin. For protein production, stably transfected cells
were grown in SFM4HEK293 medium (ThermoFisher
Scientific) with shaking at 370C and 5 % CO2. Supernatant
was harvested and processed for purification.
Purification of recombinant S1 protein
Purifications of supernatants from the recombinant yeast
cells and recombinant baculovirus infected cells were
performed in the same way. First, equal volume of wash
buffer was added to the samples (50 mM sodium phos-
phate, 0.3 M sodium chloride, 10 mM imidazole pH 8.0)
and then pH was adjusted to 8.0. Next, the samples were
passed through 0.2 μm filters to remove cellular debris
and applyed to the HisSelect Ni Affinity (Sigma Aldrich)
column. The column was washed with three sample vol-
umes of wash buffer, followed by protein elution in one
sample volume of elution buffer (50 mM sodium phos-
phate, 0.3 M sodium chloride, 250 mM imidazole
pH 8.0). The eluate was concentrated using the Amicon
Ultra-15 (EMD Millipore) filters and protein concentra-
tion was determined by a Bradford assay, and the pro-
tein quality was analysed by Western blotting.
Supernatants from HEK293T cultures were concen-
trated 5-fold by tangential flow and protein was purified
using His60 Ni Superflow (Clontech) in accordance with
the manufacturer’s instructions. Purified protein was dia-
lysed against PBS and quantified using a Bradford assay.
Glycan analysis
PNGase F and O-Glycosidase was purchased from NEB.
Briefly, 2 μg of purified S1 protein was added with 1 μL
of 10X glycoprotein denaturing buffer (NEB) in total of
10 μL of reaction volume and denatured at 95 °C for
5 min. Then, the mixture was chilled on ice for 30 s
followed by centrifugation for 10 s at 10,000 X g. Reac-
tion volume was increased to 20 μL by adding 2 μL 10X
GlycoBuffer (NEB), 2 μL 10 % NP40, water and 1 μL of
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enzyme PNGase F or 2 μL of O-glycosidase and incu-
bated at 37 °C for 1 h. The extent of glycosylation was
analyzed by mobility shift on SDS-PAGE followed by
Western blotting.
Western blotting
Protein samples were heated in the SDS sample loading
buffer (0.375 M Tris pH 6.8, 12 % SDS, 60 % glycerol,
0.6 M DTT, 0.06 % bromophenol blue) at 95 °C for
5 min. Samples were separated by electrophoresis in
10 % SDS-PAGE followed by transfer of proteins onto
nitrocellulose membrane in Towbin’s buffer (0.025 M
Tris, 0.192 M glycine, 20 % methanol) at 4 °C for 1 h at
100 V. The membrane was blocked with Blocker Blotto
(Thermo Scientific) at room temperature for 1 h. The
membrane was incubated in anti-His rabbit antibody
(1:2000) in Tris-buffered saline (0.1 M Tris, 0.9 % NaCl)
added with 0.1 % Tween-20 and 1 % skim milk at 4 °C
on orbital shaker overnight. Membrane was washed
three times in TBST, and alkaline phosphate goat anti-
rabbit IgG antibody (1:5000) was added and incubated at
room temperature for 1 h on orbital shaker. Unbound
antibody was washed by three TBST washes and bands
were visualized using an AP Conjugate Substrate Kit
(BioRad).
Pig immunization
All the animal experiments were performed in the ani-
mal containment level 3 laboratories of VIDO-InterVac.
All pigs were maintained and euthanized as per the
protocol, approved by the University of Saskatchewan’s
Animal Research Ethics Board and adhered to the Can-
adian Council on Animal Care guidelines for humane
animal use. Two commercial crossbred pregnant sows
were used in this study. The sows were vaccinated intra-
muscularly on both sides of neck with either purified S1
protein (400 μg per dose) or saline mixed with TriAdj
adjuvant [28] three times, 14 days apart (days 0, 14 and
28). Blood samples were collected for serum on days 0,
11, 28 and 35. Farrowing was induced at 16 days after
the last vaccination. Colostrum samples were collected
on the day of farrowing. Piglets were allowed to suckle
their dams, and on the 4th day of their life they were
orally challenged with live PEDV (3×102 TCID50 per
piglet). Clinical signs, diarrhea, death and weight of chal-
lenged piglets were monitored daily throughout the
study. Blood samples of all the piglets were collected on
the day of challenge for analysis. Rectal swabs were col-
lected from each of the piglets daily for analyzing the
presence of viral RNA by qRT-PCR.
Elisa
Immulon 2 HB 96-well plates (ThermoFisher Scientific)
were coated overnight with 0.1 ml/well of 0.5 μg/ml
purified recombinant S1 protein. The plates were
washed five times in phosphate buffer saline (PBS) con-
taining 0.05 % Tween 20. Sera serially diluted in assay
diluent buffer (0.1 M PBST, 0.05 % Tween-20, 1 % fish
gelatin) were added to respective wells. After a 2 h incu-
bation, the plates were washed, and 1/3000 diluted HRP-
conjugated anti-pig IgG antibodies were added. After
1 h incubation, the plates were washed, and developed
with 1-Step Ultra TMB-ELISA substrate solution (Ther-
moFisher Scientific). The reaction was stopped by add-
ing 30 μL of 2 M sulphuric acid to each well, and optical
density values were measured at 450 nm using an ELISA
plate reader.
A colostrum sample (1 mL) collected on the day of far-
rowing was treated with 30 μL rennet (5 mg/mL, Sigma-
Aldrich). The colostrum was then incubated at 37 °C for
1 h. Once solidified, the whey was separated by centrifuga-
tion at 6000 x g for 20 min. Whey samples were diluted in
PBS containing 0.05 % Tween 20 and 1 % casein and
applied at four-fold dilution on ELISA plate coated with
the purified S1 protein. Plate was incubated at room
temperature for 2 h. The plates were washed six times
with water between each step. Mouse anti-pig IgA (AbD
Serotec) was applied to the plate at 1:300 dilution and
incubated for 1 h. Donkey anti-mouse HRP conjugate
(Jackson Immunoresearch) was applied at 1:5000 dilution
and incubated for 1 h, and 1-Step Ultra TMB-ELISA sub-
strate solution (ThermoFisher Scientific) was applied to
the plates to develop the reaction. Then, the reaction was
stopped and red as described above.
Serum neutralization
The presence of PEDV-specific neutralizing antibodies in
serum of sows and piglets was determined using a serum
neutralizing (SN) test. Briefly, serum samples were diluted
2-fold and mixed with an equal volume of 200 TCID50 of
PEDV in each well. After a 1 h incubation at 37 °C,
100 μL of virus-serum mix was added to 96-well microti-
ter plate with a confluent monolayer of Vero 76 cells. The
cells were incubated for 3 h at 37 °C in 5 % CO2 and un-
bound virus particles were removed with two washes of
DMEM. Then, 100 μL DMEM supplemented with trypsin
(2 μg/mL) was added to the cells and incubated for 1 h at
37 °C in 5 % CO2. Thereafter, 100 μL DMEM containing
trypsin (2 μg/mL) and albumin (0.2 %) were added to each
well and the cells were incubated for the period of 7 days
at 37 °C in 5 % CO2. The virus neutralizing antibody titers
were expressed as the reciprocal of the highest serum di-
lution that showed no CPE in the cells. PEDV positive and
negative control sera were also included in the tests.
Viral RNA isolation and qRT-PCR
Piglet fecal swabs were collected in 0.5 ml DMEM on
every day post-infection and stored at -80 °C. RNeasy
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Plus Kit (Qiagen) was used for RNA isolation from the
faecal swab samples. qRT-PCR was conducted in two
steps: cDNA synthesis and PCR reactions. cDNA synthe-
sis was performed with 1 μL (50 ng/μL) random hexam-
ers, 1 μL of 10 mM dNTPs, and RNA in 13 μL volume
and heated at 65 °C for 5 min and chilled on ice
followed by addition of 4 μL of 5X First-strand buffer,
1 μL of 0.1 M DTT and 1 μL of RNaseOUT (Thermo-
Fisher Scientific) and 1 μL of SuperScript III enzyme
(ThermoFisher Scientific) in final volume of 20 μL. The
reaction conditions include 25 °C for 5 min, 50 °C for
60 min and 70 °C for 15 min. The PCR reaction was per-
formed in a total volume of 20 μL with 2 μl cDNA using
Power SYBR green Master Mix (Qiagen); primers (5’-
GCAACAACAGGTCCAGATCTC-3’ and 5’-CTCCACG
ACCCTGGTTATTTC-3’) were present at 0.5 μM. PCR
cycling conditions were: 95 °C for 10 min and 41 cycles of
95 °C for 15 s, 60 °C for 1 min.
Statistical analysis
All data were analyzed using the GraphPad Prism
(Version 6) software. Differences between two groups
were assessed using unpaired two-tailed t-test. Differ-
ences were considered significant if P < 0.05. Survival
curves were created using the product limit method of
Kaplan and Meier, and comparison of the curves was
done using the logrank test.
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